Microbial fermentation is one of the most versatile and transformative technologies in both the pharmaceutical and food industries. Within the biopharmaceutical sector, this technology has revolutionized the production of therapeutics, playing a crucial role in manufacturing everything from basic proteins
Kolon Biotech’s Jung Jong Cho believes that the future of cell and gene therapy lies in automation, which offers unprecedented precision and cost efficiencies. Jung Jong Cho, Vice President at Kolon Biotech, brings over two decades of expertise in biotech
Valneva SE, a specialty vaccine company, has secured a new one-year contract worth $32.8 million with the U.S. Department of Defense (DoD). Under this agreement, the DoD will purchase IXIARO, a vaccine for Japanese encephalitis (JE), with the possibility of
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ JOURNAVX (suzetrigine), a non-opioid, highly selective NaV1.8 pain signal inhibitor, for the treatment of adults with moderate-to-severe acute pain. The approval marks the first new class of pain medicine
Boston-based biotech company Leveragen Inc. has announced a strategic collaboration with Seattle-based Moonlight Bio to develop innovative T cell therapies aimed at treating some of the most challenging cancers. The partnership leverages Leveragen’s Singularity Sapiens Mouse platform, a proprietary tool
Rentschler Biopharma SE, a global CDMO, has announced a strategic shift, withdrawing from cell and gene therapy development and closing its Stevenage, UK facility. The move aligns with the company’s long-term growth strategy and response to evolving market conditions. The
AGC Pharma Chemicals, a CDMO specialising in small molecule API manufacturing, has announced a major expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities in Barcelona. The development will establish a fully integrated ecosystem, allowing seamless scale-up from early-phase
Lonza has reported CHF 6.6 billion in sales for 2024, reflecting a slight decline of 0.2% at constant exchange rates (CER). The company achieved a CORE EBITDA of CHF 1.9 billion, maintaining a 29% margin, supported by strong demand for
Helicore Biopharma, a company focused on developing novel treatments for obesity and related conditions, has announced the completion of a $65 million Series A financing round. The financing was co-led by founding investor Versant Ventures and OrbiMed, with additional participation
Atalanta Therapeutics has successfully closed a $97 million Series B financing round to support the advancement of its investigational RNA interference (RNAi) therapies for KCNT1-related epilepsy and Huntington’s disease. The financing, co-led by EQT Life Sciences and Sanofi Ventures, brings
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
